File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum

TitleThe T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum
Authors
Issue Date2012
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy and Pharmacology, 2012, v. 69 n. 6, p. 1443-1448 How to Cite?
AbstractPURPOSE: The GNAS1 gene is linked to proapoptotic signaling and correlates closely with clinical outcomes in many human cancers. The aim of this study was to evaluate whether the T393C polymorphism of the GNAS1 gene could be used as a chemotherapy sensitivity and prognosis predictive marker of advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum (GP). METHODS: In this study, we performed the PCR-restriction fragment length polymorphism assay to examine the genotypes of the GNAS1 T393C polymorphism in 131 peripheral blood DNA specimens from advanced NSCLC patients with GP treatment. RESULTS: The frequencies of the CC, CT, and TT genotypes in 131 advanced NSCLC cases were 25.2, 47.4, and 26.7%, respectively. The favorable TT genotype was significantly correlated with better overall survival (OS; P < 0.05) and longer progress-free survival (PFS; P < 0.05) compared with the CT or CC genotype. In the multivariate Cox proportional hazards model, the GNAS1 T393C polymorphism was independently associated with overall survival after adjusting the clinicopathological factors (P < 0.05). CONCLUSIONS: This study suggests that the TT genotype of the GNAS1 T393C polymorphism could be an independent prognostic marker to predict chemotherapy sensitivity, favorable OS and PFS in advanced NSCLC patients with GP treatment.
Persistent Identifierhttp://hdl.handle.net/10722/152650
ISSN
2015 Impact Factor: 2.824
2015 SCImago Journal Rankings: 1.283
ISI Accession Number ID
Funding AgencyGrant Number
Zhejiang Provincial Chinese Medicine Research Foundation2010ZB062
2011ZQ012
Zhejiang Provincial Health Bureau Foundation2010KYA032
2010KYA036
2008A015
2007B025
Wu JiePing medical foundation2011
320.6750.11059
11091
Foundation of Zhejiang Provincial Educational CommitteeY201019175
National Natural Science Foundation of China81001212
Funding Information:

This work was supported by Zhejiang Provincial Chinese Medicine Research Foundation (Grant No. 2010ZB062, 2011ZQ012), Zhejiang Provincial Health Bureau Foundation (Grant No. 2010KYA032, 2010KYA036, 2008A015, and 2007B025) and Wu JiePing medical foundation(Grant No. 2011,320.6750.11059, and 11091) and Foundation of Zhejiang Provincial Educational Committee (Grant No. Y201019175), National Natural Science Foundation of China (Grant No. 81001212).

 

DC FieldValueLanguage
dc.contributor.authorXie, FJen_US
dc.contributor.authorZhao, Pen_US
dc.contributor.authorKou, JYen_US
dc.contributor.authorHong, Wen_US
dc.contributor.authorFu, Len_US
dc.contributor.authorHu, Len_US
dc.contributor.authorHong, Den_US
dc.contributor.authorSu, Den_US
dc.contributor.authorGao, Yen_US
dc.contributor.authorZhang, YPen_US
dc.date.accessioned2012-07-16T09:45:15Z-
dc.date.available2012-07-16T09:45:15Z-
dc.date.issued2012en_US
dc.identifier.citationCancer Chemotherapy and Pharmacology, 2012, v. 69 n. 6, p. 1443-1448en_US
dc.identifier.issn0344-5704-
dc.identifier.urihttp://hdl.handle.net/10722/152650-
dc.description.abstractPURPOSE: The GNAS1 gene is linked to proapoptotic signaling and correlates closely with clinical outcomes in many human cancers. The aim of this study was to evaluate whether the T393C polymorphism of the GNAS1 gene could be used as a chemotherapy sensitivity and prognosis predictive marker of advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum (GP). METHODS: In this study, we performed the PCR-restriction fragment length polymorphism assay to examine the genotypes of the GNAS1 T393C polymorphism in 131 peripheral blood DNA specimens from advanced NSCLC patients with GP treatment. RESULTS: The frequencies of the CC, CT, and TT genotypes in 131 advanced NSCLC cases were 25.2, 47.4, and 26.7%, respectively. The favorable TT genotype was significantly correlated with better overall survival (OS; P < 0.05) and longer progress-free survival (PFS; P < 0.05) compared with the CT or CC genotype. In the multivariate Cox proportional hazards model, the GNAS1 T393C polymorphism was independently associated with overall survival after adjusting the clinicopathological factors (P < 0.05). CONCLUSIONS: This study suggests that the TT genotype of the GNAS1 T393C polymorphism could be an independent prognostic marker to predict chemotherapy sensitivity, favorable OS and PFS in advanced NSCLC patients with GP treatment.-
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.rightsThe original publication is available at www.springerlink.com-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic use-
dc.subject.meshCarcinoma, Non-Small-Cell Lung - drug therapy - genetics - mortality - pathology-
dc.subject.meshGTP-Binding Protein alpha Subunits, Gs - genetics-
dc.subject.meshLung Neoplasms - drug therapy - genetics - mortality - pathology-
dc.subject.meshPolymorphism, Genetic-
dc.titleThe T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinumen_US
dc.typeArticleen_US
dc.identifier.emailFu, L: gracefu@graduate.hku.hken_US
dc.identifier.emailZhang, YP: zhangypzj@126.com-
dc.identifier.authorityFu, L=rp01435en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00280-012-1849-3-
dc.identifier.pmid22371153-
dc.identifier.scopuseid_2-s2.0-84863808615-
dc.identifier.hkuros201865en_US
dc.identifier.volume69en_US
dc.identifier.issue6-
dc.identifier.spage1443en_US
dc.identifier.epage1448en_US
dc.identifier.isiWOS:000304622600006-
dc.publisher.placeGermany-
dc.identifier.citeulike10416985-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats